| 纯度 | > 85 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | BNP |
| Uniprot No | |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-132aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MHPLGSPGSA SDLETSGLQE QRNHLQGKLS ELQVEQTSLE PLQESPRPTG VWKSREVATE GIRGHRKMVL YTLRAPRSPK MVQGSGCFGR KMDRISSSSG LGCKVLRRH |
| 预测分子量 | |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 冻干粉 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BNP重组蛋白的3篇代表性文献摘要(作者与标题为虚构示例，仅用于格式说明)：
1. **标题**: Recombinant human BNP production in E. coli: Optimization and characterization
**作者**: Smith J, et al.
**摘要**: 本研究报道了在大肠杆菌中高效表达重组人脑钠肽(BNP)的优化策略，通过密码子优化和纯化工艺改进，获得高纯度、具有生物活性的重组BNP，为临床检测试剂开发奠定基础。
2. **标题**: Therapeutic potential of recombinant BNP in heart failure models
**作者**: Chen L, et al.
**摘要**: 通过动物实验证实重组BNP蛋白能有效改善心力衰竭模型的左室射血分数，降低心室壁压力，其利尿排钠作用与天然BNP等效，提示其在心衰治疗中的转化价值。
3. **标题**: Stability analysis of lyophilized recombinant BNP formulations
**作者**: Gupta R, et al.
**摘要**: 系统评估了冻干工艺对重组BNP蛋白稳定性的影响，发现甘露醇/蔗糖复合保护剂可显著维持蛋白二级结构，在加速稳定性试验中保持≥24个月的有效性。
注：以上为模拟文献框架，实际研究需通过PubMed/Web of Science检索关键词"recombinant B-type natriuretic peptide"获取真实文献，近5年研究多聚焦于生产工艺优化、新型给药系统开发及生物活性验证等领域。
B-type natriuretic peptide (BNP) is a cardiac hormone primarily secreted by ventricular cardiomyocytes in response to myocardial stretching and pressure overload. It plays a critical role in cardiovascular homeostasis by regulating blood pressure, fluid balance, and sodium excretion. BNP is synthesized as a preprohormone (preproBNP), which is cleaved into proBNP and further processed into the biologically active 32-amino acid peptide (BNP) and an inactive N-terminal fragment (NT-proBNP). Both BNP and NT-proBNP serve as key biomarkers for diagnosing and monitoring heart failure.
Recombinant BNP proteins are engineered using biotechnological platforms, such as *E. coli* or mammalian cell expression systems, to produce the active peptide for therapeutic or diagnostic applications. Recombinant human BNP (e.g., nesiritide) mimics endogenous BNP by binding to natriuretic peptide receptors (NPR-A), triggering cyclic GMP-mediated vasodilation, natriuresis, and diuresis. Clinically, it has been used to treat acute decompensated heart failure, though its adoption declined due to mixed efficacy and safety outcomes in trials.
In research, recombinant BNP aids in studying cardiac pathophysiology, receptor interactions, and signaling pathways. It is also utilized in developing immunoassays to measure BNP/NT-proBNP levels, critical for cardiovascular diagnostics. Challenges in production include ensuring proper post-translational modifications (e.g., disulfide bonds) for bioactivity, which often necessitates mammalian expression systems.
Overall, recombinant BNP remains a vital tool for both clinical management of heart conditions and advancing cardiovascular research, bridging insights into natriuretic peptide biology and therapeutic innovation.
×
